CLX snags Dx property

After recently increasing its investment in diagnostics company Zonda

Register for free to listen to this article
Listen with Speechify
MURRIETA, Calif.—After recently increasing its investment in diagnostics company Zonda to 41%, CLX Investment Company, Inc., announced the signing of a letter of intent to acquire all remaining issued and outstanding Zonda shares. Zonda, which specializes in medical and non-medical tests using a proprietary enzyme detection system, is expected to launch its first product in the United States at the end of Q1 2008.
"We expect that the combination of Zonda's innovative testing products and strong, experienced leadership will allow the company to become a significant player in the diagnostic testing industry," says Steven R. Peacock, CLX consultant CEO. "For these reasons, we have targeted Zonda to become the focus of operations in CLX Investment Company."
One area of particular expertise for Zonda is point-of-care (POC) platforms, which according to a February 2006 report by BCC Research, will see its U.S. market almost double in value by 2010 to more than $9.5 billion. The same report suggests that the global POC market was just over $9 billion in 2005.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue